Article Figures & Data
Figures
- Fig 1.
A, Scatterplot of aspirin reaction units (x-axis) versus aspirin dose (y-axis). There is a strong inverse correlation (P = .01). Gray area indicates aspirin resistance. B, Scatterplot of platelet inhibition (x-axis) versus clopidogrel dose (y-axis). There is no correlation (P = .64). Gray area indicates clopidogrel resistance.
Tables
Platelet Inhibition (%) Parameter Estimate (b) P Value Demographics Age (years) – −0.25 .303 Age groups (No.) −15.8 .031 <55 years (21) 53.0 >55 years (34) 37.2 Sex (No.) −2.3 .755 Women (34) 44.1 Men (21) 41.8 Medical history Hypertension (No.) −13.1 .077 No (34) 48.2 Yes (21) 35.1 Diabetes (No.) −24.0 .036 No (49) 45.8 Yes (6) 21.8 Hypercholesterolemia (No.) −11.8 .153 No (41) 46.2 Yes (14) 34.4 Coronary artery disease (No.) 2.7 .789 No (47) 43.6 Yes (8) 40.9 Prior stroke (No.) 6.7 .414 No (40) 41.4 Yes (15) 48.1 Prior TIA (No.) −11.6 .288 No (48) 44.7 Yes (7) 33.1 Statin use (No.) −13.9 .085 No (40) 47.0 Yes (15) 33.1 ACE-I use (No.) −13.5 .199 No (48) 45.0 Yes (7) 31.5 Beta blocker use (No.) −4.0 .684 No (46) 43.9 Yes (9) 39.9 Ca-channel blocker use (No.) 6.9 .671 No (52) 42.8 Yes (3) 49.7 Diuretic use (No.) −5.1 .471 No (49) 44.1 Yes (6) 35.7 Aspirin use (No.) −8.4 .562 No (3) 52.0 Yes (52) 47.7 Timing of clopidogrel initiation (No.) −0.8 .889 <3 days (14) 43.2 3–7 days (25) 44.9 >7 days (16) 40.7 Laboratory values Creatinine (mg/dL) – −22.7 .175 Glucose (mg/dL) – −0.21 .035 Hemoglobin (g/dL) – −0.55 .825 Platelet count (1,000/μL) – 0.07 .190 Angiographic features Stent indication (No.) −6.0 .490 Aneurysm (42) 45.1 Stenosis (13) 39.1 Stent location (No.) −14.7 .029 MCA/ACA/PcomA (19) 53.4 Other (36) 38.7 Outcomes Re-stenosis at 6 months (No.) 7.8 .774 No (54) 43.1 Yes (1) 50.9 Stroke or TIA at 6 months (No.) −4.8 .806 No (53) 43.4 Yes (2) 38.6 Note:— –indicates data not available; TIA, transient ischemic attack; Ca, calcium; MCA, middle cerebral artery; ACA, anterior cerebral artery; PcomA, posterior communicating artery; No., number.
- Table 2:
Multivariable linear regression model for dependent variable (percentage platelet inhibition) with the following dependent variables: indication for stenting (wide-neck aneurysm vs stenosis), location of stent (anterior circulation vs other), age >55 years, diabetes, hypertension, hypercholesterolemia, statin use, ACE-I use, and baseline glucose, creatinine, and platelet levels (n = 55)
Unstandardized Coefficients Standardized Coefficients P Value 95% CI for b b Std. Error b t Lower Bound Upper Bound (Constant) 56.84 5.55 10.249 .000 45.708 67.964 Diabetes mellitus −26.83 10.61 −0.319 −2.529 .015 −48.128 −5.540 Age <55 years −16.33 6.81 −0.303 −2.399 .020 −30.001 −2.673 Note:—CI indicates confidence interval; Std. Error, standard error.
In this issue
Jump to section
Related Articles
Cited By...
- Intravenous cangrelor and oral ticagrelor as an alternative to clopidogrel in acute intervention
- Effect of bodyweight on VerifyNow Aspirin platelet function test: a retrospective review
- Efficacy of a two-test protocol for achieving a therapeutic response to clopidogrel prior to elective endovascular intracranial aneurysm treatment and an 'induced postoperative hyper-response
- Diabetes mellitus and carotid artery plaques exhibiting high-intensity signals on MR angiography are related to increased platelet reactivity after carotid artery stenting
- Flow diverter device for the treatment of small middle cerebral artery aneurysms
- Association between CYP2C19 Polymorphisms and Outcomes in Cerebral Endovascular Therapy
- Clopidogrel Resistance in Neurovascular Stenting: Correlations between Light Transmission Aggregometry, VerifyNow, and the Multiplate
- Comparing prasugrel to twice daily clopidogrel post percutaneous coronary intervention in a Veterans Affairs population
- Tailoring platelet inhibition according to multiple electrode aggregometry decreases the rate of thrombotic complications after intracranial flow-diverting stent implantation
- Variability in initial response to standard clopidogrel therapy, delayed conversion to clopidogrel hyper-response, and associated thromboembolic and hemorrhagic complications in patients undergoing endovascular treatment of unruptured cerebral aneurysms
- Platelet function inhibitors and platelet function testing in neurointerventional procedures
- Carotid artery stenting outcomes: do they correlate with antiplatelet response assays?
- Incidence of Microemboli and Correlation with Platelet Inhibition in Aneurysmal Flow Diversion
- Prevention of stent thrombosis with reduced dose of prasugrel in two patients undergoing treatment of cerebral aneurysms with pipeline embolisation devices
- Clopidogrel Hyper-Response and Bleeding Risk in Neurointerventional Procedures
- Clopidogrel Resistance Is Associated with Thromboembolic Complications in Patients Undergoing Neurovascular Stenting
- Prevention of stent thrombosis with reduced dose of prasugrel in two patients undergoing treatment of cerebral aneurysms with pipeline embolisation devices
- Body weight: a risk factor for subtherapeutic antithrombotic therapy in neurovascular stenting
- Neuroform Stent-Assisted Coiling of Unruptured Intracranial Aneurysms: Short- and Midterm Results from a Single-Center Experience with 68 Patients
- Preinterventional Clopidogrel Response Variability for Coil Embolization of Intracranial Aneurysms: Clinical Implications
- Platelet Aggregation in Intracranial Stents May Mimic In-Stent Restenosis
- The learning curve for neuroendovascular procedures: How important is it?
- Advances in Interventional Neuroradiology
- Prevalence and Risk Factors for Aspirin and Clopidogrel Resistance in Patients with Coronary Artery Disease or Ischemic Cerebrovascular Disease